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Human African trypanosomiasis
Reto Brun, Johannes Blum, Francois Chappuis, Christian Burri
Human African trypanosomiasis (sleeping sickness) occurs in sub-Saharan Africa. It is caused by the protozoan 
parasite Trypanosoma brucei, transmitted by tsetse ﬂ  ies. Almost all cases are due to Trypanosoma brucei gambiense, 
which is indigenous to west and central Africa. Prevalence is strongly dependent on control measures, which are 
often neglected during periods of political instability, thus leading to resurgence. With fewer than 12 000 cases of this 
disabling and fatal disease reported per year, trypanosomiasis belongs to the most neglected tropical diseases. The 
clinical presentation is complex, and diagnosis and treatment diﬃ   cult. The available drugs are old, complicated to 
administer, and can cause severe adverse reactions. New diagnostic methods and safe and eﬀ  ective drugs are urgently 
needed. Vector control, to reduce the number of ﬂ  ies in existing foci, needs to be organised on a pan-African basis. 
WHO has stated that if national control programmes, international organisations, research institutes, and 
philanthropic partners engage in concerted action, elimination of this disease might even be possible.
Introduction
Human African trypanosomiasis, which is fatal if left 
untreated, aﬀ   ects rural populations in sub-Saharan 
Africa. Its prevalence has changed during the past 
100 years largely because of control and intervention 
programmes. After major outbreaks at the beginning of 
the 19th century, the disease was almost eliminated in 
the mid-1960s, followed by resurgence in the late 1990s 
and a fall in the number of cases in recent years. Although 
the present number of cases (50  000–70  000) seems 
negligible on a worldwide scale, the characteristics and 
focal distribution of the disease can have a great 
socioeconomic eﬀ  ect on aﬀ  ected villages. 
Diagnosis and treatment is unsatisfactory and needs 
more research and development. As one of the most 
neglected tropical diseases, African trypanosomiasis 
could catch the attention of initiatives and public–private 
partnerships. With new methods to diagnose and treat 
patients and to control transmission by the tsetse ﬂ  y, 
elimination of the disease might be possible.
Epidemiology
The geographical range of human African trypano  somia-
sis (sleeping sickness) is restricted to sub-Saharan Africa 
(ﬁ  gure 1), where there are suitable habitats for its vector, 
the tsetse ﬂ  y. Together with the animal form of African 
trypanosomiasis, known as nagana, human disease is a 
major cause of rural underdevelopment in sub-Saharan 
Africa. Although the disease has also been reported in 
urban and periurban areas,
1 it mainly aﬀ  ects poor and 
remote rural regions. Disease transmission occurs in 
children and adults during activities such as farming, 
hunting, ﬁ  shing, or washing clothes.
The African trypanosomes pathogenic for man belong to 
the species Trypanosoma brucei, which has three subspecies: 
T b gambiense, which causes endemic disease in central 
and west Africa; T b rhodesiense, which causes more acute 
disease in east and southern Africa (ﬁ  gure 1); and T b brucei, 
which usually infects domestic and wild animals but not 
man. The strict geographical separation between 
T b gambiense and  T b rhodesiense could soon change, 
however, because the continued spread of T b rhodesiense 
in Uganda towards the northwest might cause an overlap 
of the distributions of the two forms of disease.
2 Sporadic 
reports have appeared of disease in man caused by non-
human-pathogenic trypanosome species. These species 
are T b brucei,
3 T congolense,
4 and T evansi.
5
Three major epidemics have ravaged the continent in 
the past century.
6 The ﬁ   rst, which largely aﬀ  ected 
equatorial Africa, took place between 1896 and 1906, and 
killed an estimated 800  000 people.
7 A second major 
epidemic between 1920 and the late 1940s prompted the 
colonial powers to invest in vector control and mobile 
teams to undertake active surveillance of the 
population—two strategies that are still the pillars of 
control. These control mechanisms were initially 
eﬀ  ective, and the disease was almost eradicated in the 
early 1960s. However, after the advent of independence 
there was a collapse of surveillance and control activities 
in most endemic countries, often exacerbated by civil 
conﬂ  icts. This collapse led to a progressive re-emergence 
of the disease, which reached a peak in the late 1990s in 
the Democratic Republic of the Congo (DRC), Angola, 
Central African Republic, southern Sudan, and Uganda 
(ﬁ  gure 2).
8–14 
Since this peak of infection in the 1990s, increased 
control activities have succeeded in rolling back disease 
related to T b gambiense in several countries.
15–17 In the 
24 countries regarded as endemic for such disease, there 
was a 69% reduction in the number of reported cases 
between 1997 and 2006 (from 36 585 to 11 382). However, 
T b rhodesiense disease, which contributed only 4% (n=486) 
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Search strategy and selection criteria
We did a PubMed search using the keywords: “tsetse”, 
“trypanosomiasis”, “trypanosomes”, “sleeping sickness”, 
“T b gambiense”, “T b rhodesiense”, “treatment”, 
“pentamidine”, “suramin”, “melarsoprol”, “eﬂ  ornithine”, and 
“DFMO”, in various combinations. Additional sources were 
the Programme against African Trypanosomiasis (PAAT) 
Tsetse & Trypanosomiasis Information (2005–2008) and 
personal topic-speciﬁ  c databases of RB and CB.Seminar
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of all reported cases in 2006, showed no similar decrease 
because only a few endemic countries implemented 
control programmes.
18 However, these ﬁ  gures should be 
regarded with caution since under-reporting is known to 
mask the true burden of T b rhodesiense  disease.
19,20 The 
decrease in reported T b gambiense infections is 
encouraging, but because African trypanosomiasis mainly 
aﬀ  ects remote rural communities in regions with poor 
health infrastructures, many cases certainly remain 
undiagnosed or unreported, and the true burden of 
disease in Africa remains unknown. WHO used a ratio of 
1:3–4 to calculate the ﬁ  gure of 50 000–70 000 new cases in 
2004.
21 Hidden pockets of highly endemic T b gambiense 
disease remain, as shown by the high number of patients 
(n=1800) diagnosed and treated by Médecins Sans 
Frontières between July, 2007, and June, 2008, in two 
remote areas of Central African Republic (Batangafo) and 
DRC (Doruma and Banda) (C F, unpublished data). 
Similarly, the local burden of T b rhodesiense illness on 
individuals and health services remains high in some 
aﬀ  ected areas.
22
Human African trypanosomiasis due to T b gambiense is 
very rare in short-term tourists, but has been reported in 
immigrants, refugees, and expatriates resident for long 
periods in rural areas.
23–26 Because of its long incubation 
time and chronicity, the disease should be considered even 
if a patient’s last stay in an endemic region occurred many 
years ago. The number of tourists infected in countries 
that report the most local patients is low, probably because 
these countries are rarely visited by travellers (ﬁ  gure 1). By 
contrast, disease due to T b rhodesiense has been reported 
in short-term tourists travelling to east African game 
reserves, mainly in Tanzania,
27–30 but also in Botswana, 
Rwanda, Kenya, and Malawi.
31
Vector and parasite
Trypanosomes are transmitted by blood-feeding tsetse 
ﬂ  ies of the genus Glossina from one mammalian host to 
another. Both male and female ﬂ  ies are blood-feeders 
and can thus bring about transmission. About 30 species 
and subspecies of tsetse ﬂ  ies exist, and these are separa-
ted into three groups that prefer diﬀ  erent habitats
32 and 
show diﬀ  erent abilities to transmit T b  gambiense or 
T b rhodesiense sleeping sickness. The ﬂ  ies’ biology has 
one major peculiarity—they are viviparous. The female 
ﬂ  y deposits a fully developed larva, which burrows into 
the soil, pupates, and emerges as an adult ﬂ  y a month 
later. Newly-hatched ﬂ  ies have never been reported to be 
infected with trypanosomes. The ﬂ  y ﬁ  rst needs to feed 
on an infected mammalian host, after which the parasites 
enter the digestive tract. During the following 3–5 weeks 
they undergo several diﬀ  erentiation  steps,  including 
migration to the salivary glands, where they develop into 
the infective form. The complex process of establishment 
in the midgut and maturation in the salivary glands 
depends on many factors, some favouring and others 
inhibiting its completion (ﬁ  gure 3).
33 Completion of the 
cycle in the ﬂ  y is rare in the ﬁ  eld, in that only about 0·1% 
of ﬂ  ies carry a mature infection that can be transmitted 
when the ﬂ  y bites another host.
Trypanosomes are unicellular organisms (protozoa) 
that belong to the family Trypanosomatidae and the 
genus Trypanosoma.
34 The elongated cells are 15–30 μm 
long and constantly move with the help of a ﬂ  agellum. 
They have the cellular organisation of eukaryotic cells, 
with one tubular mitochondrion that contains the 
kinetoplast, which is a condensation of the circular 
mitochondrial DNA. In the initial phase of infection, 
trypanosomes are restricted to the lymph and blood 
systems (ﬁ  gure 4). At a later stage they are also seen in 
brain parenchyma and cerebrospinal ﬂ  uid (CSF),
35 but 
are generally extracellular. 
Normal human plasma contains a trypanosome lytic 
factor. This factor destroys trypanosomes pathogenic for 
animals, whereas T b gambiense and T b rhodesiense are 
resistant to it, each by means of a diﬀ  erent mechanism.
36 
The trypanosome lytic factor has two components, 
apolipoprotein L1 and haptoglobin-related protein, which 
are especially active when assembled in one high-density 
lipoprotein.
37 One reported human infection with T evansi 
might have been attributable to an absence of 
apolipoprotein L1 in the patient.
38 
Figure 1: Distribution of human African trypanosomiasis with incidences and risk for travellers
The black line divides the areas in which Trypanosoma brucei gambiense prevails and those in which 
Trypanosoma brucei rhodesiense predominates (J Blum, Swiss Tropical Institute).
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Trypanosomes are surrounded by a surface coat 
composed of a variant surface glycoprotein  that protects 
them from lytic factors in human plasma.
39 When 
infection occurs, this glycoprotein is recognised by the 
host’s immune system, which starts producing IgM and 
IgG antibodies. These antibodies neutralise the 
corresponding trypanosomes, leading to a decrease of 
parasitaemia. However, a few of the trypanosomes will 
have changed their surface coats to a new variant surface 
glycoprotein type that is not aﬀ  ected by the circulating 
antibodies, so that they can continue to proliferate until 
new antibodies are produced. This sequence continues, 
and the immune system is not able to eliminate the 
parasites. About 2000 variant surface glycoprotein genes, 
including many pseudogenes, are present in the genome 
of T brucei,
40,41 whereas T b gambiense probably has fewer. 
Only one such glycoprotein is expressed at a speciﬁ  c 
time. The switch occurs either by transport of a variant 
surface glycoprotein gene to one of 20 expression sites 
situated on diﬀ  erent telomeres, or by silencing of an 
active telomere and activation of a telomere on another 
chromosome. Because of this high degree of antigenic 
variation, development of a vaccine is unlikely to be 
feasible.
42
Domestic and wild animals can also become infected 
with T b gambiense
43 and T b rhodesiense. Although they do 
not fall ill, they have an epidemiological role as carriers or 
reservoir animals from which tsetse ﬂ  ies can acquire an 
infection.
44 For T b rhodesiense, which is a zoonosis that is 
usually transmitted from animals to man, cattle are an 
important reservoir,
45,46 although most wild animals species 
in game parks can harbour human-pathogenic 
trypanosomes. For T b gambiense, which is anthro-
ponotic—ie, it mostly depends on human-to-human 
transmission—man provides the main reservoir. Animals 
play a less important part, but pigs and some wild animal 
species have been reported as being a reservoir.
47,43
Clinical features 
The disease appears in two stages, the ﬁ  rst 
haemolymphatic stage and the second meningo-
encephalitic stage, which is characterised by invasion of 
the CNS. The penetration of trypanosomes through the 
blood-brain barrier is an active process
48 and occurs at or 
near intracellular junctions. Disease caused by either of 
the two parasites leads to coma and death if left untreated. 
T b gambiense infection is characterised by a chronic 
progressive course. According to models based on 
survival analysis, the estimated average duration of such 
infection is around 3 years, which is evenly divided 
between the ﬁ   rst and second stages.
49  T b rhodesiense 
disease is usually acute, and death occurs within weeks 
or months.
50
A trypanosomal chancre (a reaction at the location of 
the tsetse ﬂ  y bite) is rarely seen with T b gambiense, but 
occurs in 19% of patients infected with T b rhodesiense. 
The leading signs and symptoms of the ﬁ  rst stage are 
chronic and intermittent fever, headache, pruritus, 
lymphadenopathy, and, to a lesser extent, hepatospleno-
megaly. In the second stage, sleep disturbances and neuro-
psychiatric disorders dominate the clinical presentation. 
Fever is intermittent, with attacks lasting from a day to 
a week, separated by intervals of a few days to a month or 
longer,
51 and is rarely seen in the second stage.
52 The 
febrile episodes correspond to a type 1 inﬂ  ammatory 
reaction associated with activation of macrophage-1 cells 
and high concentrations of interferon γ, tumour necrosis 
factor, reactive oxygen intermediates or metabolites, and 
nitric oxide. This reaction controls parasite invasion and 
proliferation, but the exacerbated immune response can 
induce collateral tissue damage.
53 To alleviate parasite-
elicited pathological changes the host can mount type 2 
immune responses consisting of sequential production 
of interleukin 10 and interleukin 4 or interleukin 1 that 
can induce macrophage-2 cells with anti-inﬂ  ammatory 
Figure 2: Trypanosoma brucei gambiense: comparison between population placed under active surveillance and new cases
Number of reported cases (columns) and population screened (circles), Africa, 1939–2004. Reproduced under the creative commons licence from reference 6.
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properties.
53 The mechanism of antigenic variation on 
the surface of the parasite allows it to persist and to elicit 
new parasitic waves.
Sleep disorder is a leading symptom of the second 
stage and is the one that gave the disease its name. 
Somnographic studies have shown that the disease 
causes dysregulation of the circadian rhythm of the 
sleep/wake cycle and a fragmentation of the sleeping 
pattern rather than the frequently reported inversion of 
sleep.
54 In severe cases the circadian rhythm of prolactin, 
renin, growth hormone, and cortisol secretion 
disappears.
54,55 The neurological symptoms include 
tremor, fasciculations, general motor weakness, paralysis 
of a limb, hemiparesis, akinesia, and abnormal 
movements such as dyskinesia or chorea-athetosis. 
There might be Parkinson-like movements due to 
muscular hypertension, non-speciﬁ  c  movement 
disorders, and speech disorders. Abnormal archaic 
reﬂ  exes can also arise. These disorders are rarely seen 
during the ﬁ  rst stage and increase in frequency with the 
duration of the disease.
52,56 Psychiatric symptoms such as 
irritability, psychotic reactions, aggressive behaviour, or 
inactivity with apathy can dominate the clinical picture.
56 
In Europe, infected immigrants have sometimes been 
wrongly admitted to psychiatric clinics.
57 
Cardiac involvement documented by electrocardiogram 
(ECG) changes is frequently seen in T b gambiense 
disease, but is rarely of clinical relevance. The most 
frequent ECG changes are QTc prolongation, 
repolarisation changes, and low voltage. In T b rhodesiense 
infection, myopericarditis can be more severe.
58,59 By 
contrast with heart problems in Chagas disease, which is 
caused by another trypanosome, T cruzi, arrhythmias, 
conduction problems and blocks, and congestive heart 
failure are rare in African trypanosomiasis.
60,61 Endocrine 
disorders of the thyroid and adrenocortical function can 
take the form of hypofunction or hyperfunction, but 
rarely demand speciﬁ  c treatment.
62 These symptoms are 
more pronounced in T b rhodesiense disease.
63
The symptomatology of human African trypano-
somiasis in travellers is strikingly diﬀ  erent from the 
usual textbook descriptions of African patients, and is 
similar for both T b gambiense and T b rhodesiense 
infections,
51 presenting as an acute febrile disease with 
temperatures up to 40–41°C.
21,22 In travellers, a chancre at 
the inoculation site
24 and a trypanosomal rash
22 are more 
frequently seen, and results of laboratory tests show 
greater abnormalities than in patients from endemic 
countries. Severe haematological disorders, impaired 
kidney function, electrolyte disturbances, high 
concentrations of C-reactive protein and liver enzymes 
have been described.
26,27,64,65
A great diversity of clinical pictures can be seen in 
patients infected by T b gambiense, ranging from acute 
disease to chronic forms. Asymptomatic carriers are also 
reported.
66,67 Whereas an initial genetic characterisation 
of the infecting T b gambiense in patients in Côte d’Ivoire 
showed little  genetic polymorphism,
66 a PCR analysis 
done some years later did detect DNA of T brucei sensu 
lato in healthy carriers. These parasites might represent 
a distinct and previously unrecognised genetic group of 
trypanosomes, other than T b gambiense or T b rhodesiense. 
An infection or coinfection with these T brucei sensu lato 
could cause a slow and gradual development of 
morbidity.
68 Additionally, infections of people with 
trypanosomes thought to be non-pathogenic for man 
have been described in case reports.
69
Typically, T b rhodesiense disease progresses very rapidly; 
however, in the southern countries of east Africa, in 
particular Malawi, a more chronic form has been 
reported. These two distinct clinical forms have been 
associated with two genotypes of the SRA gene. 
Additionally, tumour necrosis factor α concentration was 
high in early-stage patients in Uganda, whereas in Malawi 
high concentrations of transforming growth factor β 
concentrations were seen.
70 However, the apparently 
Figure 3: Life cycle of African trypanosomes
In man the bloodstream forms show a polymorphism with (A) dividing (black arrows) slender forms, (B) intermediate 
forms, and (C) stumpy forms. In the tsetse ﬂ  y vector, bloodstream forms transform to (D) dividing midgut forms, then 
to (E) the migrating epimastigote forms, which develop in the salivary glands to (F) the infective metacyclic forms, 
which are injected during the next blood meal into the mammalian host. Reproduced from Vickerman K. 
Developmental cycles and biology of pathogenic trypanosomes. Br Med Bull 1985; 41: 105–14, with permission of 
Oxford University Press.
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much slower progression into the second disease stage 
in the chronic form hampers direct comparison of the 
populations and further investigation of this topic will be 
needed.
Diagnosis
The diagnosis and staging of T b gambiense disease rely 
on laboratory examinations, because the clinical features 
of the disease are not suﬃ   ciently speciﬁ  c.
23,71,72 A three-
step approach is used within control programmes and 
for individual patients: screening, diagnostic conﬁ  rma-
tion, and staging.
The card agglutination test for trypanosomiasis/
T b gambiense (CATT), developed in the late 1970s, can 
be done on serum, capillary blood obtained from a 
ﬁ  nger prick, or blood from impregnated ﬁ  lter papers.
73–75 
CATT is a fast and practical serological test that allows 
hundreds of individuals to be screened daily, and is 
reported to be 87–98% sensitive and 93–95% speciﬁ  c.
76–80 
CATT is the best-adapted and most eﬃ   cient screening 
method, and is widely used for mass population 
screening in endemic areas (ﬁ  gure 5).
81,82 However, since 
the test is used in populations where the prevalence of 
African trypanosomiasis is usually less than 5%, the 
positive predictive value of a positive CATT remains too 
low for conﬁ  rmation of the disease. There are indications 
that CATT results might be misleading in speciﬁ  c areas 
as a result of the absence of the LiTat 1·3 antigene.
83 
Other highly sensitive serological tests, such as 
immunoﬂ  uorescence or enzyme-linked immuno sorbent 
assays, are generally used in non-endemic countries to 
screen individuals with suggestive clinical features or 
previous exposure.
79,84 Since serological tests are not 
100% sensitive, health professionals are advised to 
search for trypanosomes in individuals with negative 
serological tests who have had a recent infection 
(chancre) or a strong clinical suspicion of African 
trypanosomiasis. 
The microscopic examination of lymph node aspirate 
and blood, or both, is needed for parasitological 
conﬁ   rmation. The delay between sampling and 
examination should be kept as short as possible to avoid 
lysis of trypanosomes. When present, a cervical lymph 
node is punctured and the fresh aspirate swiftly 
examined. The sensitivity of lymph node palpation and 
aspiration varies from 40% to 80% dependent on 
parasite strain, stage of disease (this test is more 
sensitive during the ﬁ  rst stage), and prevalence of other 
diseases that cause lymphadenopathy.
85,86 Because 
examination of thin or thick blood ﬁ  lms has very low 
sensitivity, concentration methods such as the 
microhaematocrit centrifugation technique,
87 quanti-
tative buﬀ  y  coat,
88,89 and miniature anion-exchange 
centrifuga tion  technique
90 should be used.
82,91,92 Serial 
examinations on consecutive days increase the sensitivity 
of blood examination techniques. Detection of parasite 
nucleic acids by PCR might become useful as a more 
sensitive approach, but existing tests need further 
standardisation and clinical validation.
71 Some 
investigators recommend treatment of individuals with 
high CATT titres (≥1:16), even if parasitological 
examination is negative, in populations with high 
disease prevalence (>1%), especially when the most 
sensitive blood detection methods (quantitative buﬀ  y 
coat or miniature anion-exchange centrifugation 
technique) cannot be used.
93,94 This strategy should not 
be applied when disease prevalence is low.
95 
Because treatment diﬀ   ers substantially between the 
ﬁ  rst and second stage, diﬀ  erentiation between them by 
examination of the CSF after lumbar puncture is 
essential.
96 According to WHO recommendations
75 the 
presence in CSF of more than ﬁ   ve white blood cells 
per μL, trypanosomes, or increased protein content 
(>370 mg/L) deﬁ  nes second-stage disease. The ﬁ  ve cells 
per μL threshold is most widely used, but some 
controversy exists about the group of patients with six to 
Figure 5: Screening for trypanosomiasis taking place under mango trees in Kajo-Keji county, Sudan
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20 cells per μL, because this group is composed of 
individuals with or without signs of neuroinﬂ  ammation 
and with various clinical responses to pentamidine, 
which is the drug used to treat ﬁ  rst-stage disease.
97–100 
Whereas the microscopic ﬁ   nding of trypanosomes is 
diagnostic of second-stage disease, the clinical 
signiﬁ   cance of a positive PCR on a CSF sample is 
controversial.
101,102 Total protein measurement in the CSF 
is no longer recommended. By contrast, increased IgM 
concentrations in CSF, caused by synthesis within the 
spinal cord, are an early and speciﬁ  c marker of CNS 
invasion.
103–105 A ﬁ  eld-designed latex agglutination test for 
IgM in CSF has shown promising results, but needs 
further validation.
106 Antibodies against neuroﬁ  laments, 
galactocerebrosides, neuroﬁ  laments, and glial ﬁ  brillary 
acidic proteins are also promising CSF markers of 
second-stage disease.
107–109
The diagnostic approach for T b rhodesiense disease 
diﬀ  ers from that for T b gambiense in several ways. First, 
there is no serological screening test for T b rhodesiense. 
Rather, the identiﬁ  cation of suspected cases relies on 
the non-speciﬁ   c clinical presentation and history of 
exposure. Second, parasitological conﬁ  rmation is easier 
for  T b rhodesiense, because the density of blood 
circulating parasites is higher than for T b gambiense. A 
thin or thick blood smear is usually suﬃ   cient to conﬁ  rm 
diagnosis. And third, biological indices such as 
haemoglobin and platelet counts, and coagulation tests 
are more frequently or substantially changed in African 
trypanosomiasis caused by T b rhodesiense than in that 
caused by T b gambiense, but these ﬁ  ndings remain 
non-speciﬁ  c.
Research and development of methods for diagnosis 
and staging of disease have been revitalised, notably 
through an initiative launched in 2006 by WHO and the 
Foundation for Innovative New Diagnostics (FIND).
110 
Present research eﬀ   orts focus on several areas: (i) 
recombinant or native trypanosome antigens that could 
be used to develop an improved serological test; (ii) 
methods to detect parasite antigens in blood or CSF; (iii) 
proteomic ﬁ   ngerprinting; (iv) low-tech PCR methods 
such as loop-mediated isothermal ampliﬁ  cation  or 
oligochromatography; and (v) new blood or CSF markers 
of second-stage disease.
111–115 
Treatment
Pentamidine
Few drugs are available to treat human African 
trypanosomiasis and selection is based mainly on the 
disease stage and causative pathogen (table). At present, 
all drugs are donated to WHO by the producers.
116,117
Pentamidine is the drug of choice for treatment of ﬁ  rst-
stage disease caused by T b gambiense. It is given 
intramuscularly for a week , unless it can be given as an 
intravenous infusion in saline over 2 h. There is 
pharmacokinetic evidence that three injections might be 
equally eﬀ  ective,
118,119 and a comparative clinical trial is in 
progress to test this strategy (trial registration 
ISRCTN55042030). By contrast, the use of pentamidine 
in intermediate-stage disease (ie, up to ten or 20 white 
blood cells per μL in CSF)
120 has produced equivocal 
outcomes
97,99,100 and should not be generally recommended. 
Attention has been drawn to an unintended modiﬁ  cation 
of the dose calculation from the base to the salt,
121 but this 
change should lead to a clariﬁ  cation of the label rather 
than a change in practice, because pentamidine at the 
currently used dose is still very eﬀ  ective. Pentamidine is 
generally well tolerated. When given by intramuscular 
injection, site pain and transient swelling, abdominal 
pain and gastrointestinal problems, and hypoglycaemia 
(5–40%) are the most frequently reported adverse 
events.
122 Other important adverse drug reactions such 
Stage Route of application Dosing Main adverse drug reactions 
Trypanosoma brucei gambiense
Pentamidine* First Intramuscular 4 mg/kg bodyweight at 24 h intervals for 7 days Hypoglycaemia, injection site pain, diarrhoea, nausea, 
vomiting
Eﬂ  ornithine Second Intravenous
Infusion of >30 min
100 mg/kg bodyweight at 6 h intervals for 
14 days
Diarrhoea, nausea, vomiting, convulsions; anaemia, 
leucopenia, and thrombocytopenia
Melarsoprol† Second Intravenous 2·2 mg/kg bodyweight at 24 h intervals for 
10 days
Encephalopathic syndromes, skin reactions (pruritus, 
maculopapular eruptions), peripheral motoric (palsy) or 
sensorial (paraesthesia) neuropathies, thrombophlebitis
Trypanosoma brucei rhodesiense
Suramin* First Intravenous Test dose of 4–5 mg/kg bodyweight at day 1, then 
ﬁ  ve injections of 20 mg/kg bodyweight every 
7 days (eg, day 3, 10, 17, 24, 31); maximum dose 
per injection 1 g
Hypersensitivity reactions (acute, late); albuminuria, 
cylinduria, haematuria, peripheral neuropathy
Melarsoprol* Second Intravenous Three series of 3·6, 3·6, 3·6 mg/kg bodyweight, 
the series spaced by intervals of 7 days; 
maximum dose per day 180 mg
Encephalopathic syndromes, skin reactions (pruritus, 
maculopapular eruptions), peripheral motoric (palsy) or 
sensorial (paraesthesia) neuropathies, thrombophlebitis
*Endemic countries: according to national legislature or guidelines. †Only where eﬂ  ornithine is not available or where melarsoprol is ﬁ  rst-line treatment according to 
national guidelines.
Table: Standard treatments for human African trypanosomiasis and main adverse reactions
For FIND see http://www.
ﬁ  nddiagnostics.orgSeminar
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as leucopenia, thrombocytopenia, hyperkalaemia, and 
QT-prolongation, which are seen in treatment of other 
diseases (eg, Pneumocystis jirovecii infection
123), are rarely 
reported, probably because of the scarcity of adequate 
methods for patient monitoring.
Suramin
Suramin is used for ﬁ  rst-stage T b rhodesiense disease, but 
is generally avoided against T b gambiense disease in 
western and central Africa because where Onchocerca spp 
are also present, its high activity against these parasites 
can expose patients to the risk of severe allergic reactions. 
The recommended dose regimens for suramin are 
complex and last up to 30 days.
124 The compound 
deteriorates rapidly in air and should be injected 
immediately after dilution in distilled water.
125 Adverse 
drug reactions are frequent but usually mild and 
reversible, including nephrotoxicity, peripheral 
neuropathy, and bone marrow toxicity with 
agranulocytosis and thrombocytopenia. Rare acute and 
late hypersensitivity reactions can occur,
32 of which the 
acute reaction is the reason for the low test dose generally 
applied before treatment initiation.  
Melarsoprol
The organoarsenic compound melarsoprol remains the 
most widely used drug for treatment of second-stage 
disease caused by T b gambiense in resource-poor 
countries where the new drug eﬂ  ornithine is not available 
or aﬀ  ordable, and it is the only choice for second-stage 
T b rhodesiense. For T b gambiense an abridged treatment 
schedule of ten injections on consecutive days was 
recommended by the International Scientiﬁ  c Council for 
Trypanosomiasis Research and Control.
126 For treatment 
of T b rhodesiense, various lengthy and complex treatment 
schedules are still used (table); work on the abridged 
schedule is continuing. Adverse reactions to melarsoprol 
are frequent and can be severe or even life-threatening. 
The most important reaction is an encephalopathic 
syndrome, which occurs with very variable frequency in 
an average 4·7% of T b gambiense and 8·0% of 
T b rhodesiense patients, with a case fatality rate of 44% 
and 57%, respectively.
127 For the management of 
encephalopathic syndrome, dexamethasone and 
diazepam are recommended.
122 Careful monitoring of the 
patient during treatment is crucial and although not 
indicative, the appearance of fever or fever combined 
with headaches can be regarded as warning signs.
128 
Skin reactions such as pruritus and maculopapular 
eruptions are fairly common, but severe complications 
such as bullous eruptions occur in less than 1% of 
cases.
78,126 Peripheral motor (palsy) or sensorial 
(paraesthesia) neuropathies have been reported. A good 
injection technique is mandatory to mitigate the irritating 
and painful eﬀ  ects of the injections, often leading to 
thrombophlebitis. In several foci, treatment failures have 
reached 30% of those treated. These failures suggest the 
emergence of  resistance to melarsoprol, in which a 
P2 adenosine transporter might be implicated.
129 So far, 
however, diﬃ   culties in retrieval of T b gambiense isolates 
from patients have hampered demonstration of parasite 
resistance.
Eﬂ  ornithine
Eﬂ  ornithine is the only new molecule for the treatment 
of human African trypanosomiasis that has been 
registered in the past 50 years. Several studies comparing 
melarsoprol with eﬂ   ornithine have shown a clearly 
reduced mortality with eﬂ  ornithine, which is therefore 
recommended as the ﬁ  rst-line treatment for second-stage 
T b gambiense disease,
130–132 but the use of eﬂ  ornithine 
against  T b rhodesiense is not advised, because this 
organism is innately less susceptible to the drug than is 
T b gambiense.
133 Treatment of T b gambiense infection 
with eﬂ  ornithine lasts for 2 weeks, and because of the 
short half-life of the drug, four short infusions per day 
are necessary (see table). This regimen hampers the 
replacement of melarsoprol by eﬂ   ornithine in rural 
public treatment facilities. The provision of kits by WHO, 
including all the necessary ancillary materials, could 
mitigate some of the diﬃ   culties.
134 Attempts were made 
to reduce the diﬃ   culty of drug administration by use of 
an oral formulation, but were abandoned after a 
pharmacokinetic trial gave discouraging results.
135,136 
Adverse drug reactions are similar to those of other 
cytostatic drugs, and include bone marrow toxicity 
leading to anaemia, leucopenia, and thrombocytopenia 
(25–50%), gastrointestinal symptoms (10–39%), and 
convulsions (7%).
137 Superimposed bacterial infection at 
the catheter site can lead to life-threatening sepsis, but 
this event can be prevented by adequate nursing care.
138 
Prevention and control
There is no vaccine against trypanosome infection, and 
chemoprophylaxis is not recommended because of the 
toxicity of the drugs and the low risk of infection. The 
only preventive measure is reduction of tsetse ﬂ  y bites. 
The ﬂ  ies are attracted to dark colours, in particular blue 
and black, and to the motion of vehicles. They can bite 
through thin clothes, and insect repellents provide only 
part protection. Travellers can take some preventive 
measures, such as avoidance of areas where tsetse ﬂ  ies 
are known to be present, travelling in cars with screened 
or closed windows in endemic foci, use of insect 
repellents, and clothes of wrist and ankle length. After a 
person is bitten by a tsetse ﬂ  y, they should be monitored, 
although the risk of an infection is low. If a chancre, 
fever, or other symptom develops, an aspirate of the 
chancre, the blood, and possibly a lymph node aspirate 
should be examined for the presence of trypanosomes. 
In T b gambiense areas the CATT could be used. 
The most important control measure for T b gambiense 
disease is active case-ﬁnding followed by treatment of the 
identiﬁed patients. Infected people can remain Seminar
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asymptomatic for long periods before they develop signs 
of sleeping sickness, but they always act as a reservoir. 
Although animals have a less important role as reservoirs 
for T b gambiense, for T b rhodesiense, domestic (cattle, 
dogs) and wild animals (mainly antelopes) provide a vast 
reservoir that should be taken into consideration for 
control.
139,140 Vector control by use of tsetse ﬂ  y traps or 
screens, in combination with odours that attract the ﬂ  ies, 
or insecticides, helps to reduce the ﬂ  y  density. 
Chemoprophylaxis is no longer in use because of the 
poor risk-beneﬁt ratio caused by the adverse eﬀ  ects of the 
drugs.
The biological cycle of human African trypanosomiasis 
is very fragile because transmission through the tsetse ﬂ  y 
is complex and slow. As a result, even in countries where 
the disease is endemic, less than 0·1% of ﬂ  ies  carry 
mature parasites. The prevalence in man is also low apart 
from in epidemic foci. If the density of ﬂ  ies and infected 
individuals is lower than crucial limits, transmission can 
break down. This situation is more likely to occur for 
disease due to T b gambiense (small animal reservoir) 
than for that caused by T b rhodesiense (substantial 
reservoir of domestic and wild animals). 
In 2002, the WHO HAT [human African trypano-
somiasis] control and surveillance programme 
established a worldwide alliance to eliminate sleeping 
sickness.
141 Even earlier, the Pan-African Tsetse and 
Trypanosomiasis Eradication Campaign (PATTEC) was 
founded as a taskforce uniting African countries aﬀ  ected 
by African trypanosomiasis to ﬁ   ght and eventually 
eliminate the disease.
142 The main strategy of PATTEC is 
elimination of the tsetse ﬂ  y in isolated foci through an 
integrated approach that combines insecticide spraying, 
traps, and the sterile insect technique. The use of sterile 
male ﬂ  ies resulted in the eradication of tsetse ﬂ  ies on 
Unguja Island in Zanzibar,
143 but the enormous cost of 
this method is likely to restrict its use, especially in areas 
where several vector species cause transmission. Many 
tsetse control experts do not share the PATTEC view, 
but rather advocate the use of simple technologies such 
as traps in combination with insecticides and 
attractants.
144 For the region endemic for T b rhodesiense 
a restricted application of insecticides to cattle (especially 
belly and legs) represents a cost-eﬀ  ective method of 
tsetse control.
145
Elimination of African trypanosomiasis is thought to 
be feasible by WHO.
15 However, a prerequisite is to have 
new reliable methods for diagnosis and staging, and new, 
safe, eﬀ  ective, and easy-to-apply drugs for both stages of 
disease. Furthermore, participation of the national 
programmes of all aﬀ   ected African countries is 
paramount. To guarantee sustainability, additional 
partners are needed—international organisations, non-
governmental organisations, and philanthropic organ-
isations—to maintain the eﬀ   ort over decades. If this 
strategy can be realised, eﬀ  orts to eliminate the disease 
will have a real chance of success. 
Research priorities
Recent eﬀ   orts have focused on ﬁ  nding  optimum 
therapeutic regimens and on development of combination 
therapy with drugs already registered or those used to 
treat related diseases. For example, the oral drug 
nifurtimox, registered for treatment of Chagas disease, 
was considered for compassionate treatment, in 
combination with other trypanocidal drugs, of patients 
who did not respond to melarsoprol.
146 Gastrointestinal 
disturbances with nausea, abdominal pains, and vomiting 
are very frequent, and neurological adverse reactions 
with general convulsions, tremor, or agitation can occur.
32 
The frequency of adverse reactions increases with 
treatment duration and all are rapidly reversible after 
discontinuation of the drug.
147
Various combinations of eﬂ  ornithine,  melarsoprol, 
and nifurtimox have been tested and in all trials the 
eﬃ   cacy was better than with monotherapy. However, 
combinations containing melarsoprol resulted in very 
high rates of severe adverse drug reactions.
146,148 As a 
result of those investigations, a multicountry trial of 
nifurtimox-eﬂ   ornithine combination therapy was 
undertaken to compare the standard eﬂ  ornithine 
therapy with an abridged regimen consisting of 
200 mg/kg of eﬂ  ornithine given as a short intravenous 
infusion every 12 h for 7 days, combined with nifurtimox 
5 mg/kg given orally every 8 h for 10 days. This regimen 
reduces the number of infusions from 56 to 14 and 
the treatment duration from 14 to 10 days.
149,150 Some 
data reported so far suggest the combination is 
rather well tolerated and has a good intermediary 
eﬀ  ectiveness.
150
The development of new medicines against human 
African trypanosomiasis underwent a serious setback 
when the new oral ﬁ  rst-stage diamidine drug, pafuramidine 
maleate (DB289), failed almost at the end of the 
development programme because of nephrotoxicity.
151,152 
However, a back-up programme identiﬁ  ed new diamidines 
that could cure a CNS mouse model of infection (JE Hall 
and R Brun, unpublished results). Currently, no molecules 
are at the stage of clinical development for treatment of 
African trypanosomiasis. However, one molecule, the 
nitroimidazole fexinidazole, has been advanced from 
discovery to the preclinical stage, and proﬁ   ling is in 
progress. If this process is successful, the ﬁ  rst phase 1 
studies in man should begin in 2009.
153,154 
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